Clinical trial
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in…
NCT00088582 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00088582 |
|---|---|
| Title | Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients |
| Official title | A Multicenter, Randomized, Crossover, Open Label Dose Finding Study to Compare the Safety, Efficacy and PK/PD Relationship of Multiple Doses of SOM230 and Sandostatin in Acromegalic Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Pasireotide (SOM230), Octreotide (Sandostatin) |
| Enrollment | 62 |
| Start date | Mar 1, 2004 |
| Primary completion | Oct 1, 2005 |
| First posted | Aug 2, 2004 |
| Last update posted | Nov 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: